Vimarsana
Biggest News Aggregation in the World

Page 42 - Immunic Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Immunic Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Immunic Inc Today - Breaking & Trending Today

DGAP-News: Immunic Receives Notice of Allowance for Composition-of-Matter Patents in the United States and in Europe for IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor - Vimarsana News

DGAP-News: Immunic Receives Notice of Allowance for Composition-of-Matter Patents in the United States and in Europe for IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor

DGAP-News: Immunic, Inc. / Key word(s): Patent Immunic Receives Notice of Allowance for Composition-of-Matter Patents in the United States and in Europe for IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor 02.02.2022 / 22:01 The issuer is solely responsible for the content of this annou...

DGAP-News: Immunic, Inc.: Immunic Receives Notice of Allowance for Composition-of-Matter Patents in the United States and in Europe for IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor - Vimarsana News

DGAP-News: Immunic, Inc.: Immunic Receives Notice of Allowance for Composition-of-Matter Patents in the United States and in Europe for IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor

DGAP-News: Immunic, Inc. / Key word(s): Patent Immunic Receives Notice of Allowance for Composition-of-Matter Patents in the United States and in Europe for IMU-935, a Potentially Best-in-Class

Immunic Receives Notice of Allowance for Composition-of-Matter Patents in the United States and in Europe for IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor - Vimarsana News

Immunic Receives Notice of Allowance for Composition-of-Matter Patents in the United States and in Europe for IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...

Mid-Morning Market Update: Markets Mostly Lower Following Monday's Rally; UPS Earnings Top Views - Vimarsana News

Mid-Morning Market Update: Markets Mostly Lower Following Monday's Rally; UPS Earnings Top Views

US stocks started the first trading day of new month on a cautious note after recording gains on Monday. Wall Street closed the volatile January m...

Immunic, Inc. Publishes Positive Results from the Single and Multiple Ascending Dose Parts of its Phase 1 Clinical Trial of IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor - Vimarsana News

Immunic, Inc. Publishes Positive Results from the Single and Multiple Ascending Dose Parts of its Phase 1 Clinical Trial of IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...